Please assess the completion status of the following clinical trial:

Trial Title: Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* ASA 1 - 2 between the ages of 18 and 64, inclusive~* Scheduled for surgical procedures with an anticipated duration of anesthesia of at least 90 minutes, without further need for muscle relaxation other than for intubation~* Scheduled for surgery in supine position~* Given written informed consent~Exclusion Criteria:~* Subjects in whom a difficult intubation because of anatomical malformations was expected~* Subjects known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction~* Subjects known or suspected to have a (family) history of malignant hyperthermia~* Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia~* Subjects receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants and Mg2+~* Subjects who had already participated in CT 19.4.205~* Subjects who had participated in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into CT 19.4.205~* Female subjects who are pregnant: in females pregnancy was to be excluded both from medical history and by an hCG test within 24 hours before surgery except in females who were not of childbearing potential i.e. at least 2 years postmenopausal or underwent tubal ligation or an hysterectomy~* Females of childbearing potential not using an acceptable method of birth control: condom or diaphragm with spermicide, vasectomized partner (\>6 months), IUD, abstinence~* Subjects giving breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): rocuronium + 16.0 mg/kg Org 25969
- 2 (Type: EXPERIMENTAL): rocuronium + 2.0 mg/kg Org 25969
- 3 (Type: EXPERIMENTAL): rocuronium + 4.0 mg/kg Org 25969
- 4 (Type: EXPERIMENTAL): rocuronium + 8.0 mg/kg Org 25969
- 5 (Type: EXPERIMENTAL): rocuronium + 12.0 mg/kg Org 25969

Based on this trial design, predict the completion outcome and termination type (if applicable).